Bilirubin Blood Test Market
Report ID: SQMIG35J2486
Report ID: SQMIG35J2486
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35J2486 |
Region:
Global |
Published Date: June, 2026
Pages:
157
|Tables:
143
|Figures:
78
Global Bilirubin Blood Test Market size was valued at USD 0.88 Billion in 2024 and is poised to grow from USD 0.93 Billion in 2025 to USD 1.45 Billion by 2033, growing at a CAGR of 5.72% during the forecast period (2026-2033).
The global market for bilirubin blood tests consists of manufacturers, laboratories and distributors of assays used for measuring serum bilirubin. Bilirubin levels are an important marker for liver function, hemolysis, and neonatal jaundice, which affect millions of people worldwide. Since the 1970s, the market moved from colorimetric methods to enzymatic and dry chemistry platforms with faster turnaround and higher precision. Point-of-care devices are driving higher growth in rural clinics. For instance, the launch of handheld analyzers in sub-Saharan Africa in 2015 reduced diagnosis time from days to minutes. This transition resulted in a high demand for reliable and low-cost test kits, driving market growth across healthcare systems globally today.
Regulatory focus on detection of hepatic disorders propels the global bilirubin blood test market, as stricter screening guidelines encourage hospitals to increase test volumes. The governments' demand for universal screening of newborns for jaundice is forcing pediatric units to buy analyzers and is spurring manufacturers to invest in automated platforms that can cut labor costs. Demand is being driven by telemedicine, as monitoring services use point-of-care bilirubin meters that send results to electronic health records, allowing clinicians to change treatment without visits. This is leading companies integrating digital connectivity into kits to create new revenue streams and improve patient outcomes, a case study of the journey from policy to technology adoption at speed.
How is AI improving accuracy and efficiency in the global Bilirubin blood test market?
AI is changing the market for the bilirubin blood test with higher accuracies and efficiencies of workflow. Machine learning models can analyze the spectral data and photometric signals and discover subtle differences in the data that human readers cannot discover. Results are more reliable. Labs can leverage automation to save time and process more samples with consistent quality. This includes work on laboratory information systems for reporting and reducing transcription errors. Real-time decision support alerts clinicians to abnormal trends and reduces time to diagnosis. Increasing adoption of bilirubin test in hospitals and point of care settings is anticipated to bolster the market growth.
Philips’ AI-powered bilirubin analyzer, announced in March 2025, combines deep learning with high-throughput optics to improve both speed and measurement accuracy. The time taken is shortened by the system’s automatic calibration and instant validation of the results. This is a good example of how AI is helping to increase efficiency and meet the growing demand of the market
Market snapshot - (2026-2033)
Global Market Size
USD 0.88 Billion
Largest Segment
Total Bilirubin Test
Fastest Growth
Indirect Bilirubin Test
Growth Rate
5.72% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global bilirubin blood test market is segmented by test type, platform, application, end-user, distribution and region. Based on test type, the market is segmented into Total Bilirubin Test, Direct Bilirubin Test and Indirect Bilirubin Test. Based on platform, the market is segmented into Laboratory Analyzers, Point-of-Care (POC) and Newborn Transcutaneous Meters. Based on application, the market is segmented into Neonatal Jaundice, Liver Function and Hemolytic Anemia. Based on end-user, the market is segmented into Hospitals, Diagnostic Labs and Clinics. Based on distribution, the market is segmented into Direct and Distributors. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
The Total Bilirubin Test segment is anticipated to lead the market owing to its being the baseline test used in routine liver function tests and neonatal screening, providing a single value to the clinicians comprising of both conjugated and unconjugated fractions. Its wide clinical application ensures continuing demand from hospitals and laboratories. Established reimbursement pathways and long standing methodological familiarity help it retain its market leadership. This core test is therefore the focus of manufacturers to scale up production and ensure reagent supply optimization, which cements its pre eminence.
However, the Direct Bilirubin Test segment is experiencing the highest growth momentum, as clinicians are increasingly looking for the accurate distinction of conjugated bilirubin to diagnose obstructive liver diseases and monitor therapeutic responses. Innovations in assays and increased insurance coverage for targeted liver diagnostics are driving adoption, with this assay being a significant driver of market growth.
Laboratory Analyzers segment has the highest share as high throughput chemistry platforms offer the accuracy, standardization and integration needed for routine bilirubin testing in centralized facilities. Their ability to run multiple assays at once lowers cost per test and fits into workflows at hospitals and reference labs, strengthening ongoing procurement. In addition, the quality control procedures in place and the vendor support also instill confidence in clinicians, helping to maintain their preference for these analyzers over other options.
Meanwhile, the segment Newborn Transcutaneous Meters is emerging as the key high growth area as non invasive photometric devices allow rapid bedside jaundice assessment without blood draws, addressing parental concerns and reducing procedural burden. The growth of the market is being fueled by technological enhancements that boost accuracy and integrate with electronic health records, thereby enhancing clinical adoption, driving unit sales and creating new avenues for early life screening.
To get detailed segments analysis, Request a Free Sample Report
North America has a large network of clinical laboratories, strong physician awareness, favorable reimbursement and a culture of early disease detection. North America has several leading diagnostic manufacturers that are heavily investing in product innovation and regulatory compliance, which will ensure the rapid introduction of high-sensitivity assay kits. Integrated health-care delivery models enable routine bilirubin screening in inpatient and outpatient settings, thus fortifying market penetration. The region’s dominance is also reinforced by strong insurance coverage and up-to-date electronic health-record systems that make test ordering and result reporting easier. Collaborative research initiatives between academia and industry further ensure ongoing improvements in assay performance, maintaining a competitive edge over other geographies.
The US bilirubin blood tests market is expected to grow owing to the presence of several specialized reference laboratories and focus on preventive health. Testing has been driven by the availability of point-of-care platforms in hospitals and clinics, and reimbursement schemes that allow for cost-effective deployment. The close collaboration between device companies and regulatory bodies enables rapid market access of advanced assay technologies, further cementing the country’s status as a benchmark for clinical accuracy and turnaround time.
The Canadian public health system ensures that all have access to essential diagnostics, which bodes well for the country’s bilirubin blood testing market. Provincial health authorities have developed standardized testing protocols and encourage consistent application in urban and rural health care settings. Partnerships between local research institutions and multinational suppliers are promoting technology transfer and adaptation of assay kits to local clinical needs. Such an environment is conducive to keeping the demand constant and improvements in the efficiency of testing continuous.
Europe’s growth is driven by harmonised regulatory standards, strong public health initiatives and a growing interest in liver health across the continent. Germany and France are marked by local supply chains powered by established diagnostic manufacturers. Healthcare reforms in the United Kingdom are helping to speed up the adoption of innovative testing solutions. European Union reimbursement schemes for collaborative approaches are encouraging equitable access and routine measurement of bilirubin in primary care. Integrated digital health platforms also facilitate seamless data interchange, enabling improved clinical decision making and higher test volumes. Further investment in research collaborations and transnational clinical networks also enhances the region’s capacity to commercialize next generation assay technologies and positions Europe as a hub for both market expansion and scientific advancement.
The Germany Bilirubin Blood Test Market is supported by a wide range of accredited laboratories and a tradition of precision engineering in diagnostic equipment. High quality reagents from leading domestic manufacturers, that adhere to stringent quality standards are available to clinicians to use. Close cooperation between health insurers and laboratory providers has led to the implementation of standardized testing protocols as routine practice, and research activities at university hospitals guarantee the ongoing refinement of assays. This ecosystem is the foundation of German dominance in the European market.
Bilirubin Blood Test Market in United Kingdom Accelerates due to proactive NHS initiatives towards early detection of hepatic disorders. The focus on decentralised testing through community clinics and tele‑medicine platforms broadens patient access, alongside fast‑track regulatory routes for rapid market introduction of novel assay formats. New biotech companies working in conjunction with academic research centers are innovating and providing more sensitive and faster testing solutions. The United Kingdom is the fastest growing market in Europe, driven by the combination of policy support and technology adoption.
France Bilirubin Blood Test Market is driven by a centralized healthcare system that encourages uniformity of diagnostic standards in the public and private sectors. National health agencies’ active participation in guideline development helps to ensure consistent use of tests, and domestic manufacturers provide reagent portfolios that are tailored to clinical practice. The collaboration of research institutions and industry accelerates the deployment of improved assay platforms and thus enhances France’s standing as a leading market in Europe.
The Asia Pacific is increasing its contribution through rapid modernisation of healthcare infrastructure, higher awareness of liver disease and increased laboratory capacity in key economies. Japan and South Korea are leading the region with advanced diagnostic ecosystems, high levels of R&D investment and strong regulatory support for innovative assay technologies. Digital health solutions are being integrated to simplify test ordering and result interpretation, facilitating wider acceptance in hospital and community settings. Demand is driven by routine screening emphasis by government health programmes and technology transfer and localization of advanced testing kits by local manufacturers partnering with global players. These factors together make Asia Pacific a potential hub of emerging market growth and scientific advances in bilirubin diagnostics.
Japan Bilirubin Blood Test Market is characterized by high laboratory automation and a strong preference for highly precise analytical methods. The leading domestic companies develop assay kits with high sensitivity and the collaboration with international partners provides access to the most modern technologies. Government health policies promote routine liver function monitoring and include bilirubin testing in routine checkups in urban and rural health facilities. Japan’s continuous investment in clinical research is further improving testing algorithms, establishing Japan as a benchmark for quality and innovation in the region.
South Korea Bilirubin Blood Test Market is flourishing with a rapid expansion of outpatient clinic network and active health management culture. Governments have great interest in early detection of disease and this has resulted in widespread use of laboratory and point-of-care testing platforms. Domestic manufacturers are focused on rapid assay development, and frequently partner with research universities to expedite product pipelines. The use of mobile health apps integrated with laboratory information systems helps to engage patients and deliver results, reinforcing South Korea’s position as a dynamic player in the Asia Pacific market.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Growing Awareness of Neonatal Jaundice
Advances in Point of Care Technology
High Cost of Automated Analyzers
Limited Access in Rural Regions
Request Free Customization of this report to help us to meet your business objectives.
The market is characterized by intense competition among major diagnostics players and rapid development of bilirubin assays to meet the growing clinical needs. A recent example is a partnership between a large laboratory network and a point-of-care device manufacturer to add bilirubin testing to handheld platforms. Another example is the strategic purchase of a niche assay developer by a global health-technology group to expand product portfolios.
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, the global bilirubin blood test market is projected to grow at 5.7% CAGR to $1.45 billion by 2033, driven primarily by increasing awareness of neonatal jaundice which pushes hospitals and labs to adopt routine screening. A second driver is the rapid expansion of point‑of‑care technology that delivers quick, accurate results at the bedside, expanding use in clinics and remote settings. The market is restrained by the high cost of automated analyzers, which limits adoption in smaller facilities and rural areas. North America remains the dominating region thanks to strong reimbursement, advanced lab networks and high physician awareness, while the total bilirubin test holds the largest share as the core assay supporting routine liver panels and newborn screening.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 0.88 Billion |
| Market size value in 2033 | USD 1.45 Billion |
| Growth Rate | 5.72% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Bilirubin Blood Test Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Bilirubin Blood Test Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Bilirubin Blood Test Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Bilirubin Blood Test Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Bilirubin Blood Test Market size was valued at USD 0.88 Billion in 2024 and is poised to grow from USD 0.93 Billion in 2025 to USD 1.45 Billion by 2033, growing at a CAGR of 5.72% during the forecast period (2026-2033).
The competitive landscape is shaped by intense rivalry among major diagnostics firms accelerating bilirubin assay development to meet rising clinical demand. Recent strategies include a joint venture between a leading laboratory network and a point‑of‑care device manufacturer to embed bilirubin testing in handheld platforms, and a strategic acquisition of a niche assay developer by a global health‑technology group to broaden product portfolios. 'Roche Diagnostics', 'Abbott Laboratories', 'Siemens Healthineers', 'Beckman Coulter (Danaher)', 'Ortho Clinical Diagnostics', 'bioMérieux SA', 'Randox Laboratories', 'Mindray Medical International', 'Tosoh Corporation', 'Radiometer Medical', 'ERBA Diagnostics Mannheim', 'Analyticon Biotechnologies', 'BioSystems SA', 'DiaSys Diagnostic Systems', 'Sentinel Diagnostics', 'Stanbio Laboratory', 'Audit Diagnostics', 'Pointe Scientific', 'Sekisui Chemical', 'EKF Diagnostics'
Growing clinical emphasis on early detection of hyperbilirubinemia encourages hospitals and laboratories to incorporate bilirubin testing into routine newborn screening, because timely identification reduces the risk of severe complications and supports better patient outcomes, which in turn motivates healthcare providers to adopt reliable assay platforms and invest in staff training, thereby expanding the overall demand for bilirubin blood tests across both developed and emerging markets and fostering broader clinical research initiatives that further validate its utility worldwide
Point-Of-Care Expansion: The shift toward decentralized diagnostics is driving rapid adoption of portable bilirubin analyzers in clinics, pharmacies, and home‑care settings. Manufacturers are integrating wireless connectivity and cloud‑based data analytics, enabling real‑time result sharing with physicians. This convenience reduces turnaround time, improves patient compliance, and supports early detection of hepatic disorders. Consequently, providers are prioritizing point‑of‑care solutions that deliver reliable quantitative measurements without reliance on central laboratories, reshaping procurement strategies and expanding market reach beyond traditional hospital environments for both adult and pediatric
Why does North America Dominate the Global Bilirubin Blood Test Market? |@12
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
